| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Joey Kwong | Q56088805 |
| Ling Li | Q61093992 | ||
| P2093 | author name string | Dan Liu | |
| Chang Xu | |||
| Xin Sun | |||
| Xiaodan Li | |||
| Yonggang Zhang | |||
| Sheyu Li | |||
| Yiyi Zhang | |||
| Haoming Tian | |||
| Qianrui Li | |||
| P2860 | cites work | A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 |
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses | Q28131633 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study | Q33387473 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| Chloroquine augments the binding of insulin to its receptor. | Q41932285 | ||
| Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 | ||
| Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients | Q41933182 | ||
| Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial | Q41936586 | ||
| Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival | Q41941085 | ||
| The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters | Q41944686 | ||
| Explaining odds ratios | Q42427206 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study | Q44383942 | ||
| Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. | Q46036146 | ||
| Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis | Q47712516 | ||
| Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China | Q47940789 | ||
| Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. | Q48274065 | ||
| Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. | Q50065429 | ||
| Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. | Q53609113 | ||
| Functional polymorphism rs189037 in the promoter region of ATM gene is associated with angiographically characterized coronary stenosis. | Q54558108 | ||
| Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype | Q58327985 | ||
| Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus | Q79376053 | ||
| Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study | Q80616378 | ||
| Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients | Q84787597 | ||
| Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort | Q33448450 | ||
| The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. | Q33848290 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| New concepts in antimalarial use and mode of action in dermatology | Q34007922 | ||
| Antimalarials--the 'real' advance in lupus | Q34297582 | ||
| Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases | Q34354276 | ||
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab | Q34368081 | ||
| 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Q34500921 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| A quality-effects model for meta-analysis | Q34727569 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study | Q35840758 | ||
| High-dose chloroquine is metabolically cardiotoxic by inducing lysosomes and mitochondria dysfunction in a rat model of pressure overload hypertrophy | Q36004316 | ||
| American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis | Q36221407 | ||
| Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus | Q36277899 | ||
| Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study | Q36573102 | ||
| Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus | Q36606667 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Cardiovascular co-morbidity in rheumatic diseases | Q36835851 | ||
| Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients | Q36877859 | ||
| Cardiotoxicity of antimalarial drugs | Q36889570 | ||
| Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus | Q37188698 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. | Q37883018 | ||
| Hydroxychloroquine: a multifaceted treatment in lupus | Q38214068 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome | Q38307931 | ||
| The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
| Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study | Q39144641 | ||
| Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Q39907371 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Q40305889 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci | Q41221755 | ||
| Antimalarial drugs in the treatment of rheumatological diseases | Q41560764 | ||
| Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort | Q41917167 | ||
| The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial | Q41917902 | ||
| Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy | Q41919785 | ||
| Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications | Q41921823 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| hydroxychloroquine | Q421094 | ||
| chloroquine | Q422438 | ||
| rheumatism | Q684924 | ||
| disease-modifying antirheumatic drug | Q810254 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1685-1695 | |
| P577 | publication date | 2018-06-11 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. | |
| P478 | volume | 12 |
| Q94957046 | A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials |
| Q91851271 | Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review |
| Q92286651 | Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome |
| Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
| Q92723486 | Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus |
| Q93062616 | Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts |
Search more.